ADPT
Adaptive Biotechnologies Corp
$20.82
-0.68 (-3.16%)
At close · Jul 7
Market Cap
$3.33B
Shares
160,044,392
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$276.98M
+54.8%
FY2025
Net Income
-$59.5M
+62.7%
FY2025
Gross Margin
74.24%
+14.5pp
FY2025
Operating Margin
-20.62%
+70.2pp
FY2025
Diluted EPS
-$0.39
+63.9%
FY2025
Operating Cash Flow
-$45.99M
+51.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $260M – $270M | $295.41M | $276.98M | $178.96M | $170.28M | $185.31M | $154.34M | $98.38M | $85.07M | $55.66M | $38.45M | |
| — | $73.09M | $71.36M | $72.08M | $75.55M | $57.91M | $49.3M | $22.53M | $22.27M | $19.67M | $15.68M | |
| — | $222.32M | $205.62M | $106.88M | $94.72M | $127.4M | $105.04M | $75.85M | $62.8M | $36M | $22.77M | |
| — | — | 74.24% | 59.72% | 55.63% | 68.75% | 68.06% | 77.1% | 73.82% | 64.67% | 59.22% | |
| — | $93.19M | $93.77M | $102.95M | $122.12M | $141.76M | $142.34M | $116.07M | $70.71M | $39.16M | $32M | |
| — | $97.87M | $94.57M | $84.76M | $88.58M | $95.6M | $95.47M | $61.36M | $38.45M | $24.49M | $16.77M | |
| — | $76.29M | $72.7M | $72.81M | $83.93M | $88.53M | $74.5M | $49.54M | $30.33M | $20.41M | $15.95M | |
| — | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.69M | |
| — | $15.1M | $16M | $17.44M | $19.6M | $20.92M | — | — | — | — | — | |
| — | — | — | $2M | — | $2.02M | — | — | — | — | $840K | |
| — | $342.13M | $334.1M | $341.51M | $397.31M | $385.49M | $363.31M | $251.2M | $163.46M | $105.42M | $82.92M | |
| — | -$46.73M | -$57.12M | -$162.55M | -$227.04M | -$200.19M | -$208.97M | -$152.82M | -$78.39M | -$49.76M | -$44.48M | |
| — | — | -20.62% | -90.83% | -133.33% | -108.03% | -135.39% | -155.33% | -92.15% | -89.39% | -115.68% | |
| — | -$31.63M | -$41.12M | -$145.11M | -$207.44M | -$179.27M | — | — | — | — | — | |
| — | $11.76M | $11.78M | $11.58M | $13.8M | $4.24M | — | — | — | — | — | |
| — | — | -$59.46M | -$159.6M | -$225.3M | -$200.37M | -$207.3M | -$146.23M | -$68.61M | — | — | |
| — | — | $0 | $0 | $0 | — | — | — | $0 | — | — | |
| — | -$49.68M | -$59.5M | -$159.49M | -$225.25M | -$200.19M | -$207.28M | -$146.23M | -$68.61M | -$46.45M | -$42.83M | |
| — | — | -21.48% | -89.12% | -132.29% | -108.03% | -134.3% | -148.63% | -80.65% | -83.44% | -111.4% | |
| — | $38K | $42K | -$103K | -$54K | -$177K | -$19K | — | — | — | — | |
| — | — | — | — | — | — | -$207.28M | -$146.23M | -$69.57M | -$46.35M | -$42.7M | |
| — | -$49.84M | -$59.41M | -$159.54M | -$220.92M | -$203.17M | -$209.31M | -$146.01M | -$67.83M | -$46.39M | -$42.92M | |
| USD/shares | — | — | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 | — | — | — |
| USD/shares | — | — | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 | — | — | — |
| shares | — | — | 151.72M | 147.1M | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 12.63M | 12.2M |
| shares | — | — | 151.72M | 147.1M | 144.38M | 142.52M | 140.35M | 131.22M | 69.17M | 12.63M | 12.2M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Mrd Business Segment | $212,334,000 | $145,529,000 | $102,739,000 | $87,144,000 |
| Immune Medicine Business | $64,642,000 | $33,428,000 | $67,537,000 | $98,164,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Immune Medicine Service Revenue | $41,300,000 | $13,500,000 | $42,600,000 | $62,800,000 | — | — | — | — |
| Development Revenue | — | — | — | — | $75,448,000 | $56,943,000 | $41,552,000 | $22,685,000 |
| Development Revenue Regulatory Milestones | — | — | — | — | $10,000,000 | $2,500,000 | $2,000,000 | $10,000,000 |
| Development Support Revenue | — | — | — | — | $65,448,000 | $54,443,000 | $39,552,000 | $12,685,000 |
| Sequencing Revenue From Coverage Policy | — | — | — | — | — | — | $1,600,000 | — |
| Sequencing Revenue From Test Deliver | — | — | — | — | — | — | $400,000 | — |
| Sequencing Revenue | — | — | — | — | $78,896,000 | $41,439,000 | $43,519,000 | $32,978,000 |